Laura Calzà, Vito Antonio Baldassarro, Alessandro Giuliani, Luca Lorenzini, Mercedes Fernandez, Chiara Mangano, Sandra Sivilia, Marco Alessandri, Marco Gusciglio, Roberta Torricella and Luciana Giardino Pages 1843 - 1852 ( 10 )
The drug discovery for disease-modifying agents in Alzheimer disease (AD) is facing a failure of clinical trials with drugs based on two driving hypotheses, i.e. the cholinergic and amyloidogenic hypotheses. In this article we recapitulate the main aspects of AD pathology, focusing on possible mechanisms for synaptic dysfunction, neurodegeneration and inflammation. We then present the pharmacological and neurobiological profile of a novel compound (CHF5074) showing both anti-inflammatory and gamma-secretase modulatory activities, discussing the possible time-window for effective treatment in an AD transgenic mouse model. Finally, the concept of cognitive reserve is introduced as possible target for preventive therapies.
Tg2576, amyloid precursor protein, cognitive reserve, neuroinflammation, translational medicine.
Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, Bologna, Italy.